Amarin Co. plc Price Target Cut to $6.00 by Analysts at Oppenheimer (AMRN)
Equities research analysts at Oppenheimer reduced their price target on shares of Amarin Co. plc (NASDAQ:AMRN) from $7.00 to $6.00 in a research note issued to investors on Monday, Analyst Ratings.Net reports. The firm currently has a “market perform” rating on the stock. Oppenheimer’s target price points to a potential upside of 19.76% from the stock’s previous close.
Several other analysts have also recently commented on the stock. Analysts at Aegis reiterated a “buy” rating on shares of Amarin Co. plc in a research note to investors on Monday. They now have a $30.00 price target on the stock. Separately, analysts at Leerink Swann reiterated an “outperform” rating on shares of Amarin Co. plc in a research note to investors on Monday. Finally, analysts at Jefferies Group reiterated a “positive” rating on shares of Amarin Co. plc in a research note to investors on Thursday. Three analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $12.05.
Shares of Amarin Co. plc (NASDAQ:AMRN) traded down 1.57% during mid-day trading on Monday, hitting $5.01. 16,889,600 shares of the company’s stock traded hands. Amarin Co. plc has a 52-week low of $5.01 and a 52-week high of $12.96. The stock’s 50-day moving average is $6.57 and its 200-day moving average is $6.46. The company’s market cap is $864.8 million.
Amarin Co. plc (NASDAQ:AMRN) last released its earnings data on Thursday, August 8th. The company reported ($0.26) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.38) by $0.12. The company had revenue of $5.50 million for the quarter. On average, analysts predict that Amarin Co. plc will post $-1.37 earnings per share for the current fiscal year.
Amarin Corporation plc (NASDAQ:AMRN) is a late-stage biopharmaceutical -company with expertise in lipid science focused on the treatment of cardiovascular disease.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.